

Antonio Jimeno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11445530/publications.pdf>

Version: 2024-02-01

95
papers

13,763
citations

66343

42
h-index

45317

90
g-index

96
all docs

96
docs citations

96
times ranked

21345
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of functional human thymic cells from induced pluripotent stem cells. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 767-781.e6.	2.9	16
2	Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. <i>Molecular Carcinogenesis</i> , 2022, 61, 664-676.	2.7	3
3	Abstract CT180: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. <i>Cancer Research</i> , 2022, 82, CT180-CT180.	0.9	0
4	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , 2021, 19, 346-357.	3.4	6
5	Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. , 2021, 9, e001615.		18
6	A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 779-788.	2.3	3
7	Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGF β ² /PD-L1 blockade-treated squamous cell carcinoma. <i>Communications Biology</i> , 2021, 4, 1005.	4.4	10
8	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	10
9	Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. <i>Cancer Research</i> , 2020, 80, 1183-1198.	0.9	12
10	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. , 2020, 8, e001095.		27
11	Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. <i>Cancer Research</i> , 2020, 80, 4185-4198.	0.9	101
12	The humanized mouse: Emerging translational potential. <i>Molecular Carcinogenesis</i> , 2020, 59, 830-838.	2.7	18
13	MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2019, 38, 7329-7341.	5.9	15
14	Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function. <i>Oral Oncology</i> , 2019, 98, 118-124.	1.5	13
15	Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers. <i>Cancer Research</i> , 2019, 79, 2722-2735.	0.9	36
16	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 461-472.	2.6	51
17	Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas. <i>Molecular Carcinogenesis</i> , 2019, 58, 666-673.	2.7	30
18	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with $\geq 25\%$ tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2019, 107, 142-152.	2.8	208

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	13.7	1,153
20	Bispecific antibodies for cancer therapy: A review. , 2018, 185, 122-134.		153
21	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. <i>Clinical Cancer Research</i> , 2018, 24, 2935-2943.	7.0	25
22	Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 215-221.	4.1	13
23	Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4949-4959.	7.0	70
24	Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1651-1663.	2.7	20
25	Inhibition of EphB4â€Ephrin-B2 Signaling Enhances Response to Cetuximabâ€Radiation Therapy in Head and Neck Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 4539-4550.	7.0	24
26	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. <i>Cancer Research</i> , 2017, 77, 3551-3563.	0.9	65
27	Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 124, 139-146.	0.6	63
28	NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 761-770.	4.9	263
29	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 7490-7497.	7.0	148
30	FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation. <i>Journal of Cell Science</i> , 2017, 130, 4051-4062.	2.0	24
31	Cancer Stem Cells in Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 31-37.	0.7	30
32	Ephrinâ€B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. <i>Molecular Carcinogenesis</i> , 2017, 56, 1189-1196.	2.7	37
33	Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 1533-1543.	4.1	84
34	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 439-447.	2.0	20
35	Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. <i>Scientific Reports</i> , 2016, 6, 38792.	3.3	18
36	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2016, 15, 337-344.e2.	2.3	33

#	ARTICLE	IF	CITATIONS
37	Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3803-3811.	4.1	34
38	Emerging from their burrow: Hedgehog pathway inhibitors for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1153-1166.	4.1	27
39	A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , 2016, 138, 195-205.	5.1	35
40	Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. <i>Cancer Research</i> , 2016, 76, 6153-6158.	0.9	189
41	Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model. <i>International Journal of Radiation Biology</i> , 2016, 92, 50-56.	1.8	3
42	A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 74-79.	1.5	32
43	Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. <i>Oral Oncology</i> , 2016, 56, 1-7.	1.5	76
44	Head and Neck Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 847-856.	4.9	185
45	DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation. <i>Frontiers in Oncology</i> , 2015, 5, 260.	2.8	17
46	An Inducible TGF- β 2-TGF β 2R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. <i>PLoS ONE</i> , 2015, 10, e0123600.	2.5	5
47	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 4356-4364.	7.0	75
48	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. <i>Oral Oncology</i> , 2015, 51, 383-388.	1.5	74
49	A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2695-2703.	7.0	132
50	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. <i>Cancer Discovery</i> , 2015, 5, 1049-1057.	9.4	343
51	Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. , 2015, 146, 1-11.		201
52	ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/ β -Catenin, Notch and PI3K/Akt Signaling Pathways. <i>PLoS ONE</i> , 2015, 10, e0121648.	2.5	61
53	Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins. <i>PLoS ONE</i> , 2014, 9, e105525.	2.5	17
54	Hedgehog Signaling Drives Radioresistance and Stroma-Driven Tumor Repopulation in Head and Neck Squamous Cancers. <i>Cancer Research</i> , 2014, 74, 7024-7036.	0.9	59

#	ARTICLE	IF	CITATIONS
55	Stereotactic Body Radiotherapy as Primary Therapy for Head and Neck Cancer in the Elderly or Patients with Poor Performance. <i>Frontiers in Oncology</i> , 2014, 4, 274.	2.8	21
56	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. <i>Future Oncology</i> , 2014, 10, 1065-1080.	2.4	8
57	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. <i>Molecular Oncology</i> , 2013, 7, 776-790.	4.6	140
58	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. <i>Clinical Cancer Research</i> , 2013, 19, 1139-1146.	7.0	24
59	Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2766-2774.	7.0	147
60	Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer. <i>Cancer Research</i> , 2013, 73, 3381-3392.	0.9	84
61	Molecular Pathways in Head and Neck Cancer: EGFR, PI3K, and More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 246-255.	3.8	46
62	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	2.6	92
63	Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2048-2055.	7.0	50
64	Patient-derived tumour xenografts as models for oncology drug development. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 338-350.	27.6	1,091
65	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2568-2568.	1.6	9
66	Phase I study of oral rigosertib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3017-3017.	1.6	3
67	PX-866 and docetaxel in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3024-3024.	1.6	4
68	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCG and EORTC-GCC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	7
69	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCG and EORTC-GCC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	12
70	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2567-2567.	1.6	1
71	Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. <i>Nature Medicine</i> , 2011, 17, 860-866.	30.7	705
72	Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5793-5800.	7.0	204

#	ARTICLE	IF	CITATIONS
73	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 340-351.	6.3	392
74	A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 311-318.	4.1	46
75	More than Markers: Biological Significance of Cancer Stem Cell-Defining Molecules. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2450-2457.	4.1	183
76	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1484-1493.	4.1	39
77	[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2697-2704.	1.6	119
78	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 310-314.	4.1	250
79	Characterizing DNA methylation patterns in pancreatic cancer genome. <i>Molecular Oncology</i> , 2009, 3, 425-438.	4.6	133
80	Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4138-4146.	7.0	79
81	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	12.6	3,755
82	Activated Epidermal Growth Factor Receptor as a Novel Target in Pancreatic Cancer Therapy. <i>Journal of Proteome Research</i> , 2008, 7, 4651-4658.	3.7	42
83	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. <i>Cancer Research</i> , 2008, 68, 2841-2849.	0.9	89
84	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3275-3284.	4.1	77
85	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 1146-1156.	3.4	165
86	Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. <i>Cancer Research</i> , 2007, 67, 2187-2196.	0.9	647
87	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 515-523.	4.1	26
88	Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1509-1516.	4.1	29
89	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1079-1088.	4.1	30
90	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. <i>Pediatric Blood and Cancer</i> , 2007, 49, 352-357.	1.5	12

#	ARTICLE	IF	CITATIONS
91	Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2006, 106, 106-111.	4.1	39
92	C-fos Assessment as a Marker of Anti-EGFR Effect. <i>Cancer Research</i> , 2006, 66, 2385-2390.	0.9	36
93	An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4652-4661.	7.0	407
94	Assessment of celecoxib pharmacodynamics in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3240-3247.	4.1	30
95	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. <i>Cancer Research</i> , 2005, 65, 3003-3010.	0.9	105